SecBot SecBot
8-K ·Filed Aug 4, 2026

IBRX

ImmunityBio, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001326110-26-000077
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The strong revenue growth trajectory and FDA acceptance of the sBLA are positive catalysts, but persistent deep losses and a history of post-earnings stock declines suggest caution. Monitor for the PDUFA date in January 2027 and any updates on the planned sBLA submission for the BCG-naive NMIBC trial.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$6.95
T+0 close · Aug 4, 2026 · via day close
Latest settled
+24.17%
T+60 · $8.63
Vs SPY
+24.39%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $6.95entry
  2. T+1 · 3mo ago +4.32%α +4.52% · $7.25
  3. T+5 · 3mo ago +9.35%α +9.45% · $7.60
  4. T+20 · 3mo ago +13.24%α +14.48% · $7.87
  5. T+60 · 20d ago +24.17%α +24.39% · $8.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth consecutive quarter of growth. The FDA accepted the sBLA for ANKTIVA in BCG-unresponsive NMIBC with a PDUFA date of Jan 6, 2027.

Key Financial Metrics

EPS
−$0.22
Revenue
$51.2M
+94.0% YoY
Rating
in line

Key Facts

  • Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially from Q1 2026.
  • First-half 2026 net product revenue of $94.8M, up 121% YoY.
  • FDA accepted sBLA for ANKTIVA in BCG-unresponsive NMIBC with papillary-only disease; PDUFA date Jan 6, 2027.
  • GAAP net loss attributable to common stockholders was $230.4M in Q2 2026 vs $92.6M in Q2 2025.
  • Adjusted net loss (non-GAAP) was $81.0M in Q2 2026 vs $89.9M in Q2 2025.
  • Cash, cash equivalents, and marketable securities totaled $357.4M as of June 30, 2026.
  • Entered exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG.
  • Eighth consecutive quarter of sequential net product revenue growth since ANKTIVA's commercial launch.

Financial Impact

Q2 2026 net product revenue of $50.7M, up 92% YoY; GAAP net loss of $230.4M; adjusted net loss of $81.0M

revenuenet lossadjusted net losscash position

Risk Factors

  • Persistent GAAP and adjusted net losses despite revenue growth.
  • High operating expenses (R&D and SG&A) continue to outpace revenue growth.
  • Significant non-cash fair value losses on convertible note and warrant liabilities due to stock price increases.
  • Historical stock performance shows large declines following prior earnings reports.
  • Dependence on successful regulatory approvals and commercial expansion of ANKTIVA.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001326110-26-000077
Document: ibrx-20260804.htm0001326110-26-000077
Document: 0001326110-26-000077-index-headers.html0001326110-26-000077
Document: 0001326110-26-000077-index.html0001326110-26-000077
Document: 0001326110-26-000077.txt0001326110-26-000077
8-K Data (Synthetic)0001326110-26-000077

Track record

11 reports on IBRX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
  2. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
  3. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
  4. Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
  5. Aug 4, 202614w ago 8-K Neutral 5/10 Viewing Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
  6. Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
  7. Jul 1, 202619w ago Insider Cluster Neutral 2/10 Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
  8. May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
  9. Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
  10. Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (9h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026